Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Engineered Drug Resistant γδ T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo- and Immunotherapy

11 Jan 2013

Abstract excerpt

Classical approaches to immunotherapy that show promise in some malignancies have generally been disappointing when applied to high-grade brain tumors such as glioblastoma multiforme (GBM). We recently showed that ex vivo expanded/activated γδ T cells recognize NKG2D ligands expressed on malignant glioma and are cytotoxic to glioma cell lines and primary GBM explants. In addition, γδ T cells extend survival and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23326319
DOI: 10.1371/journal.pone.0051805

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Engineered Drug Resistant γδ T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo- and ImmunotherapyPMID 23326319Read ↗

Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.Semantic proximity Read ↗

Peripheral blood-derived, γ9δ2 t cell-enriched cell lines from glioblastoma multiforme patients exert anti-tumoral effects in vitro.Semantic proximity Read ↗

Temozolomide resistance in glioblastoma multiformeSemantic proximity Read ↗

NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in GlioblastomaSemantic proximity Read ↗

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenograftsSemantic proximity Read ↗

Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cellsSemantic proximity Read ↗

Inhibition of the αv integrin-TGF-β axis improves natural killer cell function against glioblastoma stem cellsSemantic proximity Read ↗

Mechanism-based design of agents that selectively target drug-resistant gliomaSemantic proximity Read ↗

Engineered cells as glioblastoma therapeuticsSemantic proximity Read ↗

The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.Semantic proximity Read ↗

Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.Semantic proximity Read ↗

Mismatch repair deficiency reshapes glioblastoma through immune suppression rather than hypermutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.